VBI Vaccines Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de VBI Vaccines de 63% y 46.6% respectivamente, mientras que el BPA crecerá en un 73% al año.

Información clave

63.0%

Tasa de crecimiento de los beneficios

73.0%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	23.5%
Tasa de crecimiento de los ingresos	46.6%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	17 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

VBI Vaccines down 10% on $300M mixed shelf offering; also ends two equity offerings

Aug 26

VBI Vaccines: Recent VBI-1901 Data Supports My Bull Thesis

Jun 17

Is VBI Vaccines (NASDAQ:VBIV) A Risky Investment?

Jun 09

Is VBI Vaccines (NASDAQ:VBIV) Using Debt Sensibly?

Jan 24

VBI Vaccines: Hepatitis Vaccine Approval Can Be A Catalyst For >$1bn Valuation

Oct 31

Is VBI Vaccines (NASDAQ:VBIV) Weighed On By Its Debt Load?

Oct 06

VBI Vaccines: Turning My Focus To VBI-1901

Jul 15

VBI Vaccines (NASDAQ:VBIV) Has Debt But No Earnings; Should You Worry?

Jul 08

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:VBIV - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	59	-14	-10	-4	1
12/31/2025	34	-25	-17	-20	1
12/31/2024	14	-43	-37	-40	1
12/31/2023	9	-94	-62	-61	N/A
9/30/2023	8	-115	-70	-68	N/A
6/30/2023	2	-119	-81	-77	N/A
3/31/2023	1	-120	-80	-75	N/A
12/31/2022	1	-113	-78	-74	N/A
9/30/2022	1	-111	-77	-73	N/A
6/30/2022	1	-102	-63	-60	N/A
3/31/2022	0	-73	-55	-53	N/A
12/31/2021	1	-70	-42	-40	N/A
9/30/2021	1	-66	-40	-38	N/A
6/30/2021	1	-63	-51	-49	N/A
3/31/2021	1	-56	-47	-46	N/A
12/31/2020	1	-46	-48	-47	N/A
9/30/2020	1	-42	-40	-39	N/A
6/30/2020	2	-45	-39	-38	N/A
3/31/2020	2	-49	-44	-42	N/A
12/31/2019	2	-55	-52	-49	N/A
9/30/2019	4	-63	-54	-48	N/A
6/30/2019	4	-62	-54	-47	N/A
3/31/2019	4	-66	-58	-51	N/A
12/31/2018	3	-64	-52	-46	N/A
9/30/2018	1	-56	-51	-47	N/A
6/30/2018	1	-50	-42	-40	N/A
3/31/2018	1	-43	-33	-32	N/A
12/31/2017	1	-39	-32	-31	N/A
9/30/2017	1	-36	N/A	-30	N/A
6/30/2017	1	-33	N/A	-28	N/A
3/31/2017	1	-31	N/A	-25	N/A
12/31/2016	1	-23	N/A	-19	N/A
9/30/2016	0	-19	N/A	-14	N/A
6/30/2016	0	-31	N/A	-14	N/A
3/31/2016	1	-25	N/A	-9	N/A
12/31/2015	1	-26	N/A	-9	N/A
9/30/2015	2	-23	N/A	-8	N/A
6/30/2015	2	-6	N/A	-7	N/A
3/31/2015	2	-6	N/A	-5	N/A
12/31/2014	3	-6	N/A	-5	N/A
12/31/2013	2	-9	N/A	-5	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que VBIV siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que VBIV siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que VBIV siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (46.6% al año) de VBIV crezcan más rápidamente que los del mercado US (8.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (46.6% al año) de VBIV crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de VBIV se prevé que sea elevada dentro de 3 años.

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

VBI Vaccines Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus revenue estimates increase by 291%, EPS downgraded

Consensus EPS estimates upgraded to US$4.46 loss

Consensus revenue estimates decrease by 38%, EPS upgraded

Price target decreased by 45% to US$33.00

Consensus EPS estimates fall by 1,377%

No longer forecast to breakeven

Recent updates

VBI Vaccines Inc. has completed a Follow-on Equity Offering in the amount of $2.000001 million.

VBI Vaccines Inc. has filed a Follow-on Equity Offering in the amount of $2.000001 million.

VBI Vaccines Inc. Presents Encouraging Early Tumor Response Data from Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma

VBI Vaccines Inc. announced delayed annual 10-K filing

VBI Vaccines Inc. Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology Annual Meeting

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

VBI Vaccines Inc. Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program

VBI Vaccines Inc. Announces Interim Data from the Phase 1 Clinical Study of its Multivalent Pan-Coronavirus Vaccine Candidate, VBI-2901

VBI Vaccines Inc. Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM

Consensus revenue estimates increase by 291%, EPS downgraded

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

VBI Vaccines Inc. Announces PreHevbri® is Now Available in the Netherlands and Belgium for the Prevention of Hepatitis B in Adults

Consensus EPS estimates upgraded to US$4.46 loss

New major risk - Shareholder dilution

VBI Vaccines Inc. has completed a Follow-on Equity Offering in the amount of $18 million.

VBI Vaccines Inc. announced that it expects to receive $3 million in funding from Brii Biosciences Limited

VBI Vaccines Inc.(NasdaqCM:VBIV) dropped from Russell 2000 Dynamic Index

VBI Vaccines Inc. Announces Prehevbri® Is Now Available in the United Kingdom for the Prevention of Hepatitis B in Adults

Now 21% undervalued after recent price drop

Consensus revenue estimates decrease by 38%, EPS upgraded

Price target decreased by 45% to US$33.00

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 1,377%

Insufficient new directors

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B

VBI Vaccines Inc. Announces Health Canada Approval for Prehevbrio™ for Prevention of Hepatitis B in Adults

No longer forecast to breakeven

VBI Vaccines Presents Additional Phase 1/2A Data from VBI-1901 in Recurrent GBM At the 2022 Society for Neuro-Oncology Annual Meeting

Consensus forecasts updated

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

VBI Vaccines Announces Initiation of Phase 1 Study of Multivalent Coronavirus Vaccine Candidate, VBI-2901

VBI Vaccines: Recent Updates Have Fortified My Long-Term Outlook

VBI Vaccines Inc. Announces Presentation of Physician-Initiated Compassionate Use Data of Its 3-Antigen Hepatitis B Vaccine At the 2022 International HBV Meeting

VBI Vaccines gets up to $100M debt funding from K2 HealthVentures

VBI Vaccines Inc. Announces the Resignation of Linda C. Bain from the Board of Directors

Valneva, VBI Vaccines in pact to launch Hep B vaccine in Europe

VBI Vaccines down 10% on $300M mixed shelf offering; also ends two equity offerings

Consensus revenue estimates fall by 32%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

VBI Vaccines Inc. Announces Appointment of John Dillman as Chief Commercial Officer

VBI Vaccines Receives Non-Compliance Notice from Nasdaq

VBI Vaccines Announces New Long-Term Follow-Up Clinical Data for Its 3-Antigen Adult Hepatitis B Vaccine

VBI Vaccines Inc. Receives U.S. Food and Drug Administration Orphan Drug Designation for VBI-1901 for the Treatment of Glioblastoma

VBI Vaccines: Recent VBI-1901 Data Supports My Bull Thesis

Is VBI Vaccines (NASDAQ:VBIV) A Risky Investment?

VBI Vaccines Inc. Announces Updated Phase 2A Tumor Response and Overall Survival Data for VBI-1901

VBI Vaccines Inc. Announces UK MHRA Marketing Authorisation for Prehevbri

Consensus forecasts updated

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Forecast to breakeven in 2024

VBI Vaccines Inc. Announces New Data and Progress of VBI-2900, VBI’s eVLP Coronavirus Program

VBI Vaccines Inc., Annual General Meeting, Jun 22, 2022

VBI Vaccines Inc. Announces PreHevbrio Availability in the United States for the Prevention of Hepatitis B in Adults

Forecast to breakeven in 2024

Consensus revenue estimates fall by 49%

Consensus revenue estimates fall by 49%

No longer forecast to breakeven

Price target decreased to US$6.67

VBI Vaccines Receives Positive CHMP Opinion for 3-Antigen Hepatitis B Vaccine for Immunization Against Hepatitis B Infection in Adults in the European Union

Consensus forecasts updated

VBI Vaccines Inc. Announces Prehevbrio [Hepatitis B Vaccine (Recombinant)] Recommends by CDC Advisory Committee on Immunization Practices for the Prevention of Hepatitis B in Adults

Is VBI Vaccines (NASDAQ:VBIV) Using Debt Sensibly?

VBI Vaccines Inc. Announces Dosing of First Patient in Second Phase 2 Study in Chronic Hepatitis B Patients

Forecast to breakeven in 2024

VBI Vaccines Announces Filing of New Drug Submission for 3-Antigen Hepatitis B Vaccine to Health Canada